[go: up one dir, main page]

BRPI0716997A8 - sistema ou composição de molécula protéica, método para produção da dita composição, bem como método para selecionar célula hospedeira para produzir a dita composição, uso de célula sanguínea humana imortalizada e ácido nucléico - Google Patents

sistema ou composição de molécula protéica, método para produção da dita composição, bem como método para selecionar célula hospedeira para produzir a dita composição, uso de célula sanguínea humana imortalizada e ácido nucléico

Info

Publication number
BRPI0716997A8
BRPI0716997A8 BRPI0716997A BRPI0716997A BRPI0716997A8 BR PI0716997 A8 BRPI0716997 A8 BR PI0716997A8 BR PI0716997 A BRPI0716997 A BR PI0716997A BR PI0716997 A BRPI0716997 A BR PI0716997A BR PI0716997 A8 BRPI0716997 A8 BR PI0716997A8
Authority
BR
Brazil
Prior art keywords
composition
protein molecule
host cell
nucleic acid
producing
Prior art date
Application number
BRPI0716997A
Other languages
English (en)
Inventor
Löffler Anja
Danielczyk Antje
Baumeister Hans
Stöckl Lars
Stahn Renate
Goletz Steffen
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39157600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0716997(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06090171A external-priority patent/EP1900750A1/en
Priority claimed from EP06090190A external-priority patent/EP1911766A1/en
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of BRPI0716997A2 publication Critical patent/BRPI0716997A2/pt
Publication of BRPI0716997A8 publication Critical patent/BRPI0716997A8/pt
Publication of BRPI0716997B1 publication Critical patent/BRPI0716997B1/pt
Publication of BRPI0716997B8 publication Critical patent/BRPI0716997B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

sistema de produção totalmente humano de rendimento elevado para proteínas e anticorpos melhorados a presente invenção refere-se a um método para a produção de uma composição de molécula protéica com um padrão de glicosilação definido, compreendendo: a introdução numa célula hospedeira, a qual é uma célula sanguínea humana imortalizada, de pelo menos um ácido nucleico codificando pelo menos uma parte da referida proteína; e b) o cultivo da referida célula hospedeira sob condições as quais permitem a produção da referida composição da molécula proteica; e c) o isolamento da referida composição de molécula protéica.
BRPI0716997A 2006-09-10 2007-09-10 proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma BRPI0716997B8 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP06090162 2006-09-10
EP06090162.6 2006-09-10
EP06090171.7 2006-09-18
EP06090171A EP1900750A1 (en) 2006-09-18 2006-09-18 Fully human high yield production system for improved antibodies
EP06090190A EP1911766A1 (en) 2006-10-13 2006-10-13 Use of human cells of myeloid leukaemia origin for expression of antibodies
EP06090190.7 2006-10-13
EP07090094.9 2007-05-04
EP07090094 2007-05-04
PCT/EP2007/007877 WO2008028686A2 (en) 2006-09-10 2007-09-10 Use of human cells of myeloid leukaemia origin for expression of antibodies

Publications (4)

Publication Number Publication Date
BRPI0716997A2 BRPI0716997A2 (pt) 2013-10-15
BRPI0716997A8 true BRPI0716997A8 (pt) 2019-02-05
BRPI0716997B1 BRPI0716997B1 (pt) 2020-06-02
BRPI0716997B8 BRPI0716997B8 (pt) 2021-05-25

Family

ID=39157600

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716997A BRPI0716997B8 (pt) 2006-09-10 2007-09-10 proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma

Country Status (25)

Country Link
US (3) US9051356B2 (pt)
EP (5) EP2428224B1 (pt)
JP (3) JP5767779B2 (pt)
KR (3) KR20150126730A (pt)
CN (1) CN103436574B (pt)
AU (1) AU2007294122B2 (pt)
BR (1) BRPI0716997B8 (pt)
CA (1) CA2662226C (pt)
CU (1) CU23791A3 (pt)
CY (1) CY1116279T1 (pt)
DK (2) DK2428224T3 (pt)
EA (1) EA017622B1 (pt)
ES (2) ES2620261T3 (pt)
FI (1) FI2073842T4 (pt)
HR (1) HRP20150307T1 (pt)
IL (1) IL197459A (pt)
MX (1) MX2009002388A (pt)
NZ (1) NZ575974A (pt)
PL (1) PL2073842T5 (pt)
PT (1) PT2073842E (pt)
RS (1) RS53861B1 (pt)
SG (1) SG174792A1 (pt)
SI (1) SI2073842T1 (pt)
WO (1) WO2008028686A2 (pt)
ZA (1) ZA201001903B (pt)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3528611B2 (ja) * 1998-07-16 2004-05-17 Ｊｆｅスチール株式会社 結束材の切断方法及びその装置
AU2007294122B2 (en) 2006-09-10 2013-03-07 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1920782A1 (en) 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
WO2008135259A2 (en) * 2007-05-04 2008-11-13 Glycotope Gmbh Antibody molecule composition
GB0812277D0 (en) * 2008-07-04 2008-08-13 Fusion Antibodies Ltd Antibody and uses thereof
JP2012515922A (ja) † 2009-01-22 2012-07-12 モメンタ ファーマシューティカルズ インコーポレイテッド ＣＨＯ細胞由来の糖タンパク質産物におけるガラクトース−α−１，３−ガラクトース含有Ｎ−グリカン
WO2011003615A2 (en) 2009-07-08 2011-01-13 Glycotope Gmbh Perfusion bioreactor
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
US9051370B2 (en) 2010-08-10 2015-06-09 Glycotope Gmbh Humanized EGFR antibodies
CN103025760A (zh) 2010-08-10 2013-04-03 葛莱高托普有限公司 人源化egfr抗体
BR112013003095B1 (pt) * 2010-08-10 2023-03-28 Glycotope Gmbh Método para controle da meia-vida em circulação de um anticorpo ou um fragmento ou derivado funcional do mesmo, composições de anticorpo, seu usos e seus métodos de produção
CN103298925B (zh) 2010-12-21 2016-05-18 葛莱高托普有限公司 用于培养人髓样白血病细胞以及由其衍生的细胞的方法
AR086363A1 (es) 2011-04-21 2013-12-11 Bayer Ip Gmbh Conjugados de principio activo-ligante (adc) y el uso de los mismos
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013021279A2 (en) * 2011-08-10 2013-02-14 Lfb Biotechnologies Highly galactosylated antibodies
WO2013026887A1 (en) 2011-08-22 2013-02-28 Glycotope Gmbh Microorganisms carrying a tumor antigen
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
BR112014032169A2 (pt) 2012-07-18 2017-08-01 Glycotope Gmbh tratamentos terapêuticos com anticorpos anti-her2 tendo uma fucosilação baixa
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US20150353959A1 (en) 2013-01-18 2015-12-10 Glycotope Gmbh Peptides for enhancing protein expression
TW201444870A (zh) * 2013-02-13 2014-12-01 Lab Francais Du Fractionnement 高度半乳糖基化的抗ｈｅｒ２抗體及其用途
TW201506041A (zh) 2013-02-13 2015-02-16 Lab Francais Du Fractionnement 高度半乳糖基化的抗腫瘤壞死因子阿爾法抗體及其用途
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
TW201444871A (zh) * 2013-02-13 2014-12-01 Lab Francais Du Fractionnement 具有修飾的糖化作用之西妥昔單抗及其用途
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014143343A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv core lipid binding domain monoclonal antibodies
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
BR112015023239A8 (pt) 2013-03-14 2018-04-17 Abbott Lab ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
BR112015023355A8 (pt) 2013-03-14 2018-01-30 Abbott Lab antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
EP3754012A1 (en) * 2013-03-15 2020-12-23 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
WO2014173886A1 (en) 2013-04-22 2014-10-30 Glycotope Gmbh Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR102329024B1 (ko) 2013-12-23 2021-11-19 바이엘 파마 악티엔게젤샤프트 키네신 스핀들 단백질(ksp)과의 항체 약물 접합체 (adcs)
KR102150481B1 (ko) * 2014-03-05 2020-09-02 울트라제닉스 파마수티컬 인코포레이티드 시알화 당단백질 조성물 및 이의 용도
US20150307546A1 (en) * 2014-04-29 2015-10-29 Georgia Tech Research Corporation Thermo-responsive lectin-elp fusion binding ligands for glycoprotein purification by affinity precipitation
CN105820248A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
LU92659B1 (en) * 2015-02-23 2016-08-24 Glycotope Gmbh Glycooptimized antibody drug conjugates
ES2764457T3 (es) 2015-03-31 2020-06-03 Glycotope Gmbh Vectores de expresión eucariotas que incluyen elementos reglamentarios de los grupos de genes de globina
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
AR104956A1 (es) 2015-06-09 2017-08-30 Glycotope Gmbh MÉTODO MEJORADO PARA LA PRODUCCIÓN DE POLIPÉPTIDOS g-CARBOXILADOS
WO2016207089A1 (de) 2015-06-22 2016-12-29 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
US10973923B2 (en) 2015-06-23 2021-04-13 Bayer Pharma Aktiengesellschaft Site specific homogeneous with KSP inhibitors
WO2016207328A1 (en) 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3347380B1 (en) * 2015-09-11 2024-09-25 Nascent Biotech, Inc. Enhanced delivery of drugs to the brain
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US20170114127A1 (en) 2015-10-22 2017-04-27 Massachusetts Institute Of Technology Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation
WO2017162733A1 (en) * 2016-03-22 2017-09-28 Glycotope Gmbh Iga antibodies with enhanced stability
KR20180123047A (ko) 2016-03-24 2018-11-14 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
ES2982085T3 (es) 2016-06-20 2024-10-14 Octapharma Ag Medios y métodos para modificar alelos múltiples
FR3060394B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
FR3060395B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-her2
WO2018114578A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
CA3047522A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
WO2018138113A1 (en) 2017-01-27 2018-08-02 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
JP6829357B2 (ja) * 2017-03-17 2021-02-10 住友ベークライト株式会社 抗体の糖鎖検出法
JP2020515532A (ja) 2017-03-29 2020-05-28 グリコトープ ゲーエムベーハー Ｍｕｃ１およびｃｄ３に結合する多重特異的抗体構築物
JP2020512382A (ja) * 2017-03-29 2020-04-23 グリコトープ ゲーエムベーハー Ｐｄ−ｌ１抗体およびｔａ−ｍｕｃ１抗体
EP3601348A1 (en) 2017-03-29 2020-02-05 Glycotope GmbH Humanized anti-cd40 antibodies
JP2020534814A (ja) * 2017-09-06 2020-12-03 エアウェイ・セラピューティクス・インコーポレイテッド サーファクタントタンパク質ｄ（ｓｐ−ｄ）を調製するための方法、組成物、及び細胞
CN111741971A (zh) 2017-09-06 2020-10-02 气道治疗公司 用于制备表面活性蛋白d(sp-d)的方法和组合物
BR112020015202A2 (pt) * 2018-03-01 2020-12-29 Glycotope Gmbh Construções de proteínas de fusão compreendendo um anticorpo anti-muc1 e il-15
HRP20230787T1 (hr) 2018-05-18 2023-10-27 Glycotope Gmbh Anti-muc1 antitijelo
CA3147420A1 (en) * 2019-07-26 2021-02-04 Abl Bio Inc. Anti-egfr/anti-4-1bb bispecific antibody and use thereof
TW202128745A (zh) 2019-12-06 2021-08-01 美商再生元醫藥公司 抗ｖｅｇｆ蛋白組合物及其製備方法
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
US12415864B2 (en) 2020-06-30 2025-09-16 Pentixapharm Ag Humanized antibodies against Lewis Y
AU2023234686A1 (en) 2022-03-16 2024-08-29 Pentixapharm Ag Antibodies against lypd3
WO2025099324A1 (en) 2023-11-10 2025-05-15 Tixapharm Ag Antibodies against cd44
WO2025132836A1 (en) 2023-12-19 2025-06-26 Pentixapharm Ag Antibodies against cd24

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
AU2353384A (en) * 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4931275A (en) * 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
US5683674A (en) * 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
DK0573551T3 (da) 1991-02-27 2003-08-04 Micromet Ag Serinrige peptidlinkere
AU683413B2 (en) 1992-04-13 1997-11-13 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
DE4329004A1 (de) 1993-08-28 1995-03-09 Max Delbrueck Centrum Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis
AU7965694A (en) * 1993-10-15 1995-05-04 Curators Of The University Of Missouri, The Dna encoding the human p2u receptor and null cells expressing p2u receptors
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5888773A (en) * 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997040182A1 (de) 1996-04-19 1997-10-30 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
ATE243045T1 (de) * 1997-11-20 2003-07-15 Vical Inc Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
AUPP816899A0 (en) 1999-01-14 1999-02-11 Food Technology Innovations Pty Limited Improved microbial products
EP1399538A2 (en) 1999-03-02 2004-03-24 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
JP4488579B2 (ja) * 1999-03-30 2010-06-23 日本たばこ産業株式会社 モノクローナル抗体の製造方法
EP1167537B1 (en) * 1999-03-30 2008-07-23 Japan Tobacco Inc. Process for producing monoclonal antibody
ES2601882T5 (es) 1999-04-09 2021-06-07 Kyowa Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
JP2003519096A (ja) 1999-08-18 2003-06-17 アルタレックス コーポレーション Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法
US7147850B2 (en) * 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
EP1216055A2 (en) * 1999-09-30 2002-06-26 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
FR2809312B1 (fr) 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JPWO2002030954A1 (ja) * 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
JPWO2002061118A1 (ja) 2001-02-01 2004-06-03 株式会社ヤクルト本社 発酵乳飲食品中のビフィドバクテリウム属細菌の腸内到達度評価方法
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
AU2002336981A1 (en) 2001-08-17 2003-03-03 Charite Glycoconjugates of sialic acid derivates, methods for their production and use thereof
CA2464368A1 (en) * 2001-10-22 2003-05-01 Applied Research Systems Ars Holding N.V. Compositions of fsh with high sialylation degree and their use for the preparation of medicaments
GB0125473D0 (en) 2001-10-24 2001-12-12 Syngenta Ltd Chemical process
EP1451217A4 (en) * 2001-11-20 2005-10-12 Atgen Co Ltd NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES
WO2004009632A2 (de) 2002-07-22 2004-01-29 Nemod Immuntherapie Ag Verfahren zur herstellung eines immunstimulatorischen muzins (muc1)
DK1530628T3 (da) 2002-08-16 2011-01-10 Glycotope Gmbh Fremgangsmåde til fremstilling af temperaturinducerede tumorcellelysater til anvendelse som immunogene forbindelser
DE10256900A1 (de) * 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DK1654353T3 (da) * 2003-08-18 2013-08-26 Glycotope Gmbh Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
FR2861080B1 (fr) * 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
US20050203010A1 (en) * 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
CN1926242B (zh) 2004-02-13 2013-01-16 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
JP4904266B2 (ja) 2004-07-26 2012-03-28 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 抗−ｔｆ−抗原抗体の治療的使用
US20090046556A1 (en) 2006-02-14 2009-02-19 Koninklijke Philips Electronics N.V. Bit detection for optical disc reading
WO2007124992A1 (en) 2006-04-28 2007-11-08 Unilever N.V. Method of manufacturing a cultured edible product comprising omega-3 polyunsaturated fatty acids
AU2007294122B2 (en) 2006-09-10 2013-03-07 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1911766A1 (en) 2006-10-13 2008-04-16 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1900750A1 (en) 2006-09-18 2008-03-19 Glycotope Gmbh Fully human high yield production system for improved antibodies
EP1920782A1 (en) * 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
EP2291086A1 (en) 2008-05-13 2011-03-09 Glycotope GmbH Fermentation process
EP2420515A4 (en) 2009-04-16 2013-08-28 Univ Tokyo DIAGNOSIS AND TREATMENT OF CANCER WITH ANTI-TMPRSS11E ANTIBODY
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US20150353959A1 (en) 2013-01-18 2015-12-10 Glycotope Gmbh Peptides for enhancing protein expression
JP2015138634A (ja) 2014-01-22 2015-07-30 株式会社オートネットワーク技術研究所 端子金具付き電線及びその製造方法

Also Published As

Publication number Publication date
EP2428224A3 (en) 2012-05-09
JP2015146819A (ja) 2015-08-20
DK2073842T4 (da) 2024-01-15
EP3539981A1 (en) 2019-09-18
JP5767779B2 (ja) 2015-08-19
DK2073842T3 (da) 2015-04-13
BRPI0716997A2 (pt) 2013-10-15
JP2017123879A (ja) 2017-07-20
EP2428224B1 (en) 2016-12-21
KR20170021375A (ko) 2017-02-27
ES2533964T5 (es) 2024-05-09
JP2010502204A (ja) 2010-01-28
WO2008028686A2 (en) 2008-03-13
ES2533964T3 (es) 2015-04-16
EP2428225A2 (en) 2012-03-14
KR101603632B1 (ko) 2016-03-16
IL197459A (en) 2015-08-31
EP2073842A2 (en) 2009-07-01
EP2073842B2 (en) 2023-10-18
US20100028947A1 (en) 2010-02-04
PL2073842T5 (pl) 2024-12-02
CU23791A3 (es) 2012-03-15
PT2073842E (pt) 2015-04-07
SI2073842T1 (sl) 2015-05-29
CN103436574B (zh) 2016-08-10
US10280230B2 (en) 2019-05-07
RS53861B1 (sr) 2015-08-31
EP2428223A2 (en) 2012-03-14
CA2662226C (en) 2020-08-04
FI2073842T4 (fi) 2024-01-15
AU2007294122B2 (en) 2013-03-07
JP6166303B2 (ja) 2017-07-19
EP2073842B1 (en) 2014-12-31
KR20090077911A (ko) 2009-07-16
US20190359731A1 (en) 2019-11-28
MX2009002388A (es) 2009-06-02
HRP20150307T1 (hr) 2015-04-24
US9051356B2 (en) 2015-06-09
ES2620261T3 (es) 2017-06-28
ZA201001903B (en) 2010-11-24
SG174792A1 (en) 2011-10-28
US20150368363A1 (en) 2015-12-24
AU2007294122A1 (en) 2008-03-13
EP2428223A3 (en) 2012-05-16
EA017622B1 (ru) 2013-01-30
EA200970263A1 (ru) 2009-08-28
KR20150126730A (ko) 2015-11-12
CN103436574A (zh) 2013-12-11
BRPI0716997B8 (pt) 2021-05-25
EP2428224A2 (en) 2012-03-14
PL2073842T3 (pl) 2015-06-30
DK2428224T3 (en) 2017-03-27
WO2008028686A3 (en) 2008-06-12
BRPI0716997B1 (pt) 2020-06-02
CA2662226A1 (en) 2008-03-13
CY1116279T1 (el) 2017-02-08
EP2428225A3 (en) 2012-05-09
IL197459A0 (en) 2011-08-01
NZ575974A (en) 2012-03-30

Similar Documents

Publication Publication Date Title
BRPI0716997A8 (pt) sistema ou composição de molécula protéica, método para produção da dita composição, bem como método para selecionar célula hospedeira para produzir a dita composição, uso de célula sanguínea humana imortalizada e ácido nucléico
BRPI0620803B8 (pt) anticorpo isolado ou fragmento de anticorpo anti-her-3, seu processo de preparação, composição farmacêutica e kit compreendendo o mesmo, molécula de ácido nucléico codificando o referido anticorpo, vetor compreendendo o mesmo, microrganismo transgênico, bem como método para diagnosticar uma doença associada a her-3
BR112012007821A2 (pt) polipeptídeos para ligação ao "receptor de produtos finais de glicação avançada" bem como composições e métodos envolvendo os mesmos
BRPI0706801B8 (pt) método de purificação de cardiomiócitos ou cardiomiócitos programados derivado de células-tronco ou fetos
BRPI0922106A2 (pt) anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
ATE481483T1 (de) Verfahren zur herstellung eines rekombinanten polyklonalen proteins
AR080942A1 (es) Produccion de proteinas heteromultimericas
BR112012009289A8 (pt) Método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp)
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
WO2008005847A3 (en) Method of producing factor viii proteins by recombinant methods
BRPI0607315A2 (pt) polinucleotìdeo isolado, vetor de expressão, composição, método de produzir uma molécula de ligação de antìgeno, molécula de ligação de antìgeno e o uso da mesma-, método para detectar in vivo ou in vitro a presença de egfr em uma amostra, célula hospedeira engendrada, composição farmacêutica e o uso da mesma
BR112015023262A2 (pt) anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112012026471A2 (pt) conjugado, processo para a síntese do mesmo, método para imagem de uma célula que expressa um transportador de neurotransmissor que compreende o contato da referida célula com o conjugado, processo para preparar um comporto de fórmula (ii) e (xiv) e composto
WO2007130453A3 (en) Non-natural amino acid substituted polypeptides
CL2013000019A1 (es) Proteina fijadora de antigeno aislada que fija el factor de crecimiento epidermico fijador de heparina (hg-egf); molecula de acido nucleico que la codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad hiperproliferativa.
BR112014019277A8 (pt) Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica
WO2011069992A3 (en) Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
BRPI1006270A8 (pt) ''anticorpo anti a5b1, molécula de ácido nucleio isolado, célula hospedeira, método de produção de um anticorpo anti a5b1, imunoconjugado, composição farmacêutica, método de detecção de proteína a5b1, método de tratamento de um indivíduo e kit de detecção de a5b1
ATE521695T1 (de) Zirkuläres dna-molekül mit einem konditionalen replikationsursprung, verfahren zur herstellung davon und ihre verwendung in der gentherapie
EA201070071A1 (ru) Клон клеток, продуцирующих fsh
BR112012023822A2 (pt) métodos para produzir um variante de fitase, para melhorar o valor nutricional de uma ração animal, para o tratamento de proteínas vegetais, para sintetizar um produto de fermentação, e para produzir etanol, variante de fitase, polinucleotídeo, construto de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, planta transgênica ou parte da planta, composição, processo para reduzir os níveis de fitase no esterco animal, e, uso do variante de fitase ou da composição na ração animal
YU91403A (sh) Antitela specifična za cd44v6
BR112013031590A2 (pt) compostos de ligação ao adrenorreceptor beta1 humano (beta1-ar) e seu uso na medida de anticorpos auto-anti-beta1-ar
BRPI0406265B8 (pt) método para análise por eletroforese capilar, método para pesquisa e tipagem de proteínas monoclonais, método de preparação de anticorpos modificados sobrecarregados negativamente e kit para detecção e tipagem de proteínas monoclonais
EA201071226A1 (ru) Искусственный каркас белка

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/06/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF